Soltamox Savient Pharmaceuticals, Inc. - Treatment for Breast Cancer
Soltamox is an oral liquid formulation of tamoxifen, indicated for the treatment of breast cancer in adjuvant and metastatic settings and to reduce risks of breast cancer in women with ductal carcinoma in situ (DCIS) and reduction of breast cancer incidence in women with high risk of breast cancer.Posted: October 2005
Related articles
- Savient Pharmaceuticals, Inc. Submits New Drug Application for Soltamox to the U.S. Food and Drug Administration - January 6, 2005
Soltamox (tamoxifen) FDA Approval History
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.
